SCHEMBL20183776

SCHEMBL20183776

CCn1c(=O)cc(N2CCOCC2)c2cc(NC(=O)c3ccc(Cl)cc3)ccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.61
MAPT P10636 7/20 0.61
MEN1 O00255 7/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
LMNA P02545 4/20 0.61
HTT P42858 2/20 0.61
MAPK1 P28482 2/20 0.61
NPC1 O15118 6/20 0.52
RAB9A P51151 5/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ENPP2 Q13822 1/20 0.51
POLB P06746 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
CNR2 P34972 1/20 0.50
TSHR P16473 1/20 0.50
TP53 P04637 1/20 0.50
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 4/20 0.47
NPY5R Q15761 2/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20195221 0.89 MEN1 (0.47) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL20183732 0.88 ENPP2 (0.47) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL23253945 0.86 MAPT (0.45) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL20183733 0.82 HIF1A (0.41) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL20354153 0.81 KMT2A (0.46) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL20183704 0.78 MAPT (0.48) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL21473965 0.78 MAPT (0.51) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL20183856 0.78 MAPT (0.50) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL21549485 0.77 MAPT (0.47) KMT2AMAPTMEN1SMN1; SMN2LMNA
SCHEMBL20195131 0.76 ALDH1A1 (0.44) KMT2AMAPTMEN1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108137505-B Nitrogen-containing heterocyclic compound 富士胶片株式会社 2021-07-06 CN disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10696637-B2 Nitrogen-containing heterocyclic compound FUJIFILM CORPORATION (JP) 2020-06-30 US disclosed
US-10633343-B2 2020-04-28 US disclosed
US-10633343-B2 2020-04-28 US disclosed
EP-3563851-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM Corporation (JP) 2019-11-06 EP disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORPORATION (JP) 2019-10-17 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORPORATION (JP) 2019-03-14 US disclosed
WO-2018124180-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR 富士フイルム株式会社 2018-07-05 WO disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed
EP-3327004-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Fujifilm Corporation (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987349-B2 Antitumor agent and bromodomain inhibitor BRD4, BRD1, BRD3 KMT2A 359/4885MAPT 3928/4885MEN1 1349/4885
US-10696637-B2 Nitrogen-containing heterocyclic compound CXCL10, CCL5, CXCR3 KMT2A 3299/4885MAPT 4325/4885MEN1 524/4885
US-20190314360-A1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR BRD4, BRD1, BRD3 KMT2A 359/4885MAPT 3928/4885MEN1 1349/4885
US-20190077761-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND CXCL10, CCL5, CXCR3 KMT2A 3299/4885MAPT 4325/4885MEN1 524/4885
US-10633343-B2 CXCL10, CCL5, CXCR3 KMT2A 3171/4885MAPT 4406/4885MEN1 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.